Search
Black Diamond Therapeutics Inc
BDTXAdd to Watchlist
2.010USD
+0.170+9.24%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
114.46MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+9.24%
5 Days
+17.54%
1 Month
-3.83%
6 Months
-19.28%
Year to Date
-17.28%
1 Year
-22.09%
Key Figures
1.830Open
2.035High
1.58MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.77%Turnover Ratio
1.840Prev. Close
1.830Low
2.14MTurnover
LossP/E Static
0.91P/B
0.00%Div Yield TTM
-27.95%ROA
4.94052wk High
0.76Volume Ratio
-69.68MNet Profit
56.94MShares
-0.7624EPS TTM
3.25Beta
-35.16%ROE
1.93052wk Low
11.14%Amplitude
100.00%Gross Margin
114.46MMarket Cap
-2.45Reward/Risk
4.88%Risk Rate
TradingKey Stock Score of Black Diamond Therapeutics Inc
Currency: USD Updated: 2026-07-02Key Insights
Black Diamond Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 49 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 9.86.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Black Diamond Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Black Diamond Therapeutics Inc Highlights
StrengthsRisks
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Growing
The company is in a growing phase, with the latest annual income totaling USD 70.00M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Undervalued
The company’s latest PE is -2.64, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 45.02M shares, decreasing 24.96% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 15.52K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.43.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
9.667
Target Price
+425.36%
Upside Space
Black Diamond Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Black Diamond Therapeutics Inc Info
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Ticker SymbolBDTX
CompanyBlack Diamond Therapeutics Inc
CEOVelleca (Mark A)
Websitehttps://www.blackdiamondtherapeutics.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Black Diamond Therapeutics Inc (BDTX)?
The current price of Black Diamond Therapeutics Inc (BDTX) is 2.01.
What is the symbol of Black Diamond Therapeutics Inc?
The ticker symbol of Black Diamond Therapeutics Inc is BDTX.
What is the 52-week high of Black Diamond Therapeutics Inc?
The 52-week high of Black Diamond Therapeutics Inc is 4.94.
What is the 52-week low of Black Diamond Therapeutics Inc?
The 52-week low of Black Diamond Therapeutics Inc is 1.93.
What is the market capitalization of Black Diamond Therapeutics Inc?
The market capitalization of Black Diamond Therapeutics Inc is 114.46M.
Is Black Diamond Therapeutics Inc (BDTX) currently rated as Buy, Hold, or Sell?
According to analysts, Black Diamond Therapeutics Inc (BDTX) has an overall rating of Buy, with a price target of 9.67.
What is the Earnings Per Share (EPS TTM) of Black Diamond Therapeutics Inc (BDTX)?
The Earnings Per Share (EPS TTM) of Black Diamond Therapeutics Inc (BDTX) is 0.39.